.png)
Bioreactors are specialized vessels that provide a controlled environment for biological processes involving cells, microorganisms, or biochemical reactions. They are the backbone of modern biotechnology and pharmaceutical manufacturing, enabling the efficient production of vaccines, therapeutic proteins, monoclonal antibodies, biosimilars, enzymes, and cell- or gene-based therapies.
By 2025, bioreactors are used across multiple industries, with over 65,000 functional units installed worldwide. Of these, about 45% are stainless-steel stirred-tank reactors designed for large-scale biologics and industrial fermentation, while 38% are single-use bioreactors (SUBs), which are increasingly preferred for flexibility and contamination control. The remaining 17% are wave, airlift, or custom modular designs catering to niche applications such as stem cell research or food-grade fermentation.
What Are Bioreactor Companies?
Bioreactor companies are specialized manufacturers and suppliers that design, produce, and deliver bioreactor systems to research institutes, pharmaceutical giants, biotechnology firms, and industrial players. Their portfolios often include:
- Stirred-Tank Bioreactors for large-scale culture processes.
- Single-Use Bioreactors designed for flexibility, faster turnaround, and contamination control.
- Wave and Airlift Bioreactors for niche applications.
- Custom Bioprocess Systems integrated with automation and digital monitoring.
The leading companies in the sector—such as Thermo Fisher Scientific, Sartorius AG, Danaher Corporation, and Merck Millipore—not only manufacture bioreactors but also provide integrated bioprocessing solutions, consumables, and digital process optimization tools.
USA Growing Bioreactor Market in 2025
The United States has emerged as the global hub for bioreactor innovation and commercialization. In 2025, over 45% of large-scale biologics production facilities in North America operate advanced single-use bioreactors. U.S.-based pharmaceutical giants and biotech startups are investing heavily in flexible manufacturing infrastructure to meet rising demand for biosimilars, vaccines, and cell-based therapies.
Key highlights for the U.S. market in 2025:
- More than 380 biopharmaceutical companies in the U.S. have integrated bioreactors in their production lines.
- The FDA’s approval of new cell and gene therapies has driven rapid adoption of 10–2000L single-use bioreactors.
- Academic centers such as MIT, Harvard, and Stanford operate cutting-edge research facilities that collaborate with commercial players like Thermo Fisher and Sartorius.
How Big is the Bioreactor Industry in 2025?
The global bioreactor industry in 2025 is valued at approximately USD 22.8 billion, supported by more than 65,000 active systems worldwide across pharmaceutical, academic, and industrial settings.
Stainless-steel bioreactors account for the largest share with a market value of around USD 10.5 billion (~45%), while single-use bioreactors contribute close to USD 8.6 billion (~38%) and other formats such as wave, airlift, and modular designs make up USD 3.7 billion (~17%). By end-use, pharmaceutical and biotechnology companies dominate with nearly USD 12.5 billion (~55% of total market value), followed by academic and research institutions at USD 4.5 billion (~20%), food and industrial fermentation applications at USD 3.4 billion (~15%), and cell and gene therapy facilities accounting for USD 2.4 billion (~10%). Regionally, North America leads the market at USD 9.0 billion (~40%), Europe follows with USD 6.8 billion (~30%), Asia-Pacific stands at USD 4.5 billion (~20%), while the Middle East & Africa contribute around USD 1.5 billion (~7%) and Latin America adds USD 1.0 billion (~3%).
In addition to scale, bioreactors are critical enablers of innovation: more than 200 clinical trials for cell and gene therapies in 2025 depend on these systems, and over 5 billion vaccine doses annually are produced through bioreactor-enabled processes, underscoring their indispensable role in global health and biotechnology.
Global Distribution of Bioreactor Manufacturers by Country in 2025
| Country / Region | Approx. # Manufacturers (2025) | Key Highlights | Representative Companies |
|---|---|---|---|
| United States | 35+ | Major hub for large-scale biologics and single-use innovation; strong R&D and CMO presence. | Thermo Fisher, Danaher/Cytiva, GE Healthcare (Cytiva), Eppendorf |
| Germany | 25+ | Engineering excellence and strong industrial fermentation & biosimilars cluster. | Sartorius, Merck Millipore, Bioengineering AG, Eppendorf |
| Switzerland | 12+ | Precision engineering and system integrators supporting niche and industrial projects. | Bioengineering AG, Infors HT, Solaris |
| India | 15+ | Rising domestic biosimilars & vaccine manufacturing; growing exports to SEA and ME. | Praj Hipurity Systems, Local integrators |
| China | 18+ | Rapid scale-up for vaccines and biosimilars; strong domestic supply chain growth. | Austar, Celltain Biotech, Local OEMs |
| Rest of Europe (UK, Netherlands, France, etc.) | 20+ | Strong R&D hubs, pilot-scale specialists and academic-industry collaboration networks. | Applikon (Netherlands), Various SMEs |
Regional Market Share and Opportunities (2025)
In 2025, the global bioreactor industry demonstrates a highly regionally diverse footprint, with each geography contributing to the overall market in distinct ways. North America remains the largest regional market, accounting for around 40% of the global industry value, equivalent to approximately USD 9.0 billion. The United States alone represents more than 26,000 installed systems and remains the primary hub for single-use bioreactors, large-scale biologics production, and advanced therapy medicinal products. Key opportunities in this region are tied to the expansion of over 1,200 biopharma facilities upgrading upstream suites, alongside strong demand from contract manufacturing organizations (CMOs) supporting cell and gene therapy pipelines.
Europe follows with roughly 30% of the global market, valued at about USD 6.8 billion in 2025, with Germany, Switzerland, France, and the Netherlands leading installations. The region counts more than 19,500 active bioreactor systems, supported by government-funded biotech hubs and strong academic-industry collaboration. Opportunities in Europe are increasingly linked to biosimilars production and sustainability, as more than 150 large installations in 2025 integrated energy-efficient and solvent recovery designs to align with EU sustainability frameworks.
Asia-Pacific has emerged as the fastest-expanding region, representing around 20% of the global industry, or USD 4.5 billion in 2025. China alone accounts for 8,000+ systems, while India surpasses 2,000 active installations, driven by vaccine production and biosimilar manufacturing. Regional opportunities are significant, with 220+ CMO projects announced or under construction across China, India, South Korea, and Singapore—most requiring single-use or hybrid bioreactor systems in the 500–5,000L range. Asia-Pacific suppliers such as Austar, Celltain Biotech, and Praj Hipurity Systems are increasingly competitive alongside global leaders like Sartorius and Thermo Fisher.
The Middle East & Africa represent around 7% of the global market, valued at approximately USD 1.5 billion in 2025, with around 5,000 installed systems. While smaller in scale, the region shows strong project-driven demand, led by government-backed vaccine production hubs in the United Arab Emirates, Saudi Arabia, and South Africa. More than 35 national biotech and vaccine initiatives were active in 2025, creating opportunities for turnkey solutions, localization, and workforce training.
Latin America accounts for close to 3% of the global industry, or about USD 1.0 billion in 2025, supported by an installed base of 3,000–3,500 bioreactors. Brazil dominates the regional landscape, representing almost half of installations due to biosimilars production and agricultural biotechnology. Mexico follows, with demand from academic institutes and food-tech fermentation projects. Regional opportunities are largely in modernization, as 120+ pilot projects were underway in 2025 requiring new 50–500L systems.
Overall, regional opportunities in 2025 are defined by different strategic needs: advanced therapies in North America, sustainability and biosimilars in Europe, rapid vaccine and biosimilar scale-up in Asia, government-backed capacity in MEA, and modernization of academic and pilot facilities in Latin America. This geographic diversity ensures that global bioreactor suppliers can align product portfolios with specific regional growth levers
Global Growth Insights unveils the top List Global Bioreactor Companies:
| Company | Headquarters | CAGR (%) | Revenue (2024) | Geographic Presence | Key Highlight |
|---|---|---|---|---|---|
| Danaher Corporation | Washington, D.C., USA | ~7% | USD 23.9 Bn | Global (60+ countries) | Owns Cytiva; leader in single-use and integrated bioprocess solutions |
| GE Healthcare (Cytiva) | Marlborough, MA, USA | ~6% | USD 6.5 Bn | 40+ global sites | Known for Xcellerex™ single-use bioreactors; strong CMO partnerships |
| Solaris Biotech | Mantua, Italy | ~5% | USD 150 Mn | Europe, North America, Asia | Specialist in lab & pilot bioreactors; IoT-enabled systems |
| Praj Hipurity Systems Ltd. | Pune, India | ~6% | USD 120 Mn | India, SEA, ME, Europe | Custom bioreactors & purification systems; vaccine production partnerships |
| Infors HT | Bottmingen, Switzerland | ~5% | USD 85 Mn | Europe, North America, Asia | Labfors & Minifors benchtop bioreactors; digital twin technology |
| Thermo Fisher Scientific, Inc. | Waltham, MA, USA | ~7% | USD 43.5 Bn | Global (100+ countries) | HyPerforma™ single-use bioreactors; end-to-end bioprocess solutions |
| Applikon Biotechnology (Getinge) | Delft, Netherlands | ~5% | USD 95 Mn | Europe, NA, Asia | Lab & pilot bioreactors; automated parallel systems |
| Austar | Shanghai, China | ~6% | USD 200 Mn | China, SEA, Europe, USA | Bioprocess equipment & cleanroom systems; vaccine partnerships |
| Sartorius AG | Göttingen, Germany | ~7% | USD 4.2 Bn | Global (60+ sites) | BIOSTAT STR® single-use leader; digitalized bioprocess platforms |
| Merck Millipore (Merck KGaA) | Darmstadt, Germany | ~6% | USD 10.8 Bn | 70+ countries | Mobius® single-use bioreactors; upstream + downstream expertise |
| Bioengineering AG | Wald, Switzerland | ~4% | USD 75 Mn | Europe, NA, Asia | Large-scale stainless-steel reactors; industrial fermentation focus |
| Solida Biotech | Berlin, Germany | ~5% | USD 50 Mn | Europe, North America, Asia | Modular single-use & lab reactors; strong in academic collaborations |
| Celltain Biotech | Shanghai, China | ~5% | USD 60 Mn | China, SEA, Europe | Single-use bioreactors 200–2000L; vaccine & biosimilar support |
| Eppendorf AG | Hamburg, Germany | ~5% | USD 1.4 Bn | Global (Europe, NA, Asia) | BioFlo® & CelliGen® benchtop systems; digital process upgrades |
Latest Company Updates Summary (2025)
- Danaher & GE Healthcare (Cytiva): Expanding AI-driven bioreactor monitoring and continuous bioprocessing solutions.
- Thermo Fisher Scientific: Introduced a 5,000L HyPerforma DynaDrive system, boosting commercial biologics production.
- Sartorius AG & Merck Millipore: Major facility expansions in Europe and North America to meet single-use demand.
- Solaris Biotech, Infors HT, Solida Biotech: Focused on lab-scale, modular, and IoT-enabled solutions.
- Praj Hipurity Systems & Austar: Strengthening regional markets in India and China for vaccine and biosimilar production.
- Eppendorf AG: Enhancing digital integration in bench-top bioreactors.
- Bioengineering AG & Celltain Biotech: Driving large-scale and cost-effective solutions in Europe and Asia.
Regional Deep-Dive — Bioreactor Market 2025
North America (United States & Canada)
North America accounts for roughly 40% of global bioreactor installations in 2025, with an installed base exceeding 26,000 systems across research, pilot, and commercial scales. The U.S. houses more than 380 biopharmaceutical companies that actively deploy bioreactors for biologics, vaccines and cell & gene therapies; this concentration makes the region the largest single market for single-use systems, bench-scale units, and integrated process platforms. Key players active in the region include Danaher (Cytiva), Thermo Fisher Scientific, Sartorius AG, Merck Millipore, Eppendorf, and GE Healthcare/Cytiva, all of which maintain manufacturing, R&D, or major distribution hubs in the U.S. Specific opportunities in North America: expansion of contract manufacturing organizations (CMOs/CROs) requiring 500 L to 5,000 L single-use lines, retrofitting legacy stainless-steel plants with hybrid single-use modules, and deployment of digital process control systems — more than 1,200 U.S. facilities were reported to be modernizing their upstream suites by 2025.
Europe (Western, Central & Northern Europe)
Europe represents approximately 30% of installations globally in 2025, with an installed base near 19,500 systems. Germany, Switzerland, France, and the Netherlands are hotspots: Germany hosts more than 25 leading bioreactor manufacturers or major suppliers, including Sartorius AG, Merck KGaA (Millipore), and Bioengineering AG. Switzerland is notable for precision engineering firms and system integrators. In 2025, European demand is driven by biosimilars production, advanced R&D hubs, and government-backed biotech clusters; over 800 university and institute labs across Europe use bench and pilot bioreactors for process development. European companies are emphasizing sustainability: more than 150 large bioreactor installations in 2025 incorporated energy-efficient designs or solvent recovery systems. Active suppliers in Europe include Applikon, Infors HT, Eppendorf, Sartorius, and Bioengineering AG.
Asia-Pacific (China, India, Japan, South Korea, Southeast Asia)
Asia-Pacific is the fastest expanding adopter by installations and holds about 20% of the global installed base in 2025, with roughly 13,000 systems in operation. China and India together contribute the bulk of this figure: China accounts for an estimated 8,000+ installations and India for 2,000+ installations, reflecting rapid scale-up in vaccine, biosimilars, and biopharma contract manufacturing. Local companies active in the region include Austar, Celltain Biotech, Praj Hipurity Systems, and growing local arms of Thermo Fisher, Sartorius, and Merck. In 2025, Asia-Pacific opportunities are concrete: more than 220 new CMO facilities were announced or under construction across China, India, South Korea and Singapore, many specifying single-use capability in the 1,000 L to 5,000 L range. Additional drivers include regional vaccine manufacturing programs that required deployment of medium to large stainless-steel bioreactors for national immunization strategies.
Middle East & Africa (MEA)
MEA accounted for roughly 6–8% of global installations in 2025, translating to an installed base near 5,000 systems across the region. While overall volume is smaller, demand is highly project-driven: national vaccine and biotech initiatives in the United Arab Emirates, Saudi Arabia, and South Africa represented about 35 large scale projects in 2025 that required turnkey bioprocessing suites. Key opportunities include strategic government investments in local manufacturing capacity, incentivized joint ventures with western and Asian suppliers, and training programs for local bioprocess engineers. Companies with active projects or distribution in MEA in 2025 included Danaher, Thermo Fisher, Sartorius, and regional partners of Praj and Austar providing localized builds and service.
Latin America (Brazil, Mexico, Argentina, Chile)
Latin America held about 4–5% of global installed systems in 2025, with an installed base near 3,000–3,500 bioreactors focused on academic, vaccine and food-fermentation uses. Brazil and Mexico are the largest national markets: Brazil accounted for approximately 45% of the region’s installations, driven by a mix of biosimilar production and agricultural biotech fermentation projects. Regional opportunities include modernization of legacy vaccine plants, pilot facilities for biotech startups, and fermentation applications in food tech — more than 120 pilot projects were recorded region-wide in 2025 seeking 50 L to 500 L systems. Suppliers active in Latin America in 2025 range from global vendors (Thermo Fisher, Sartorius, Eppendorf) to regional integrators providing local service and validation.
Cross-Regional Themes & Infrastructure Needs (2025)
Across all regions in 2025, five dominant infrastructure needs emerged with measurable footprints: (1) single-use adoption — single-use systems comprised roughly 38% of new installations that year; (2) digital monitoring — over 2,500 facilities added AI or advanced analytics modules to bioreactors for process control; (3) CMO capacity expansion — more than 1,700 CMO projects globally specified upgraded upstream suites; (4) training and workforce — an estimated 10,000 bioprocess engineers and technicians required upskilling between 2023 and 2025; (5) local supply chains — Asia and Europe led in expanding regional manufacturing of single-use consumables, reducing lead times for critical supplies.
FAQ — Global Bioreactor Companies (2025)
Q1. Which companies dominate the bioreactor industry?
The leading companies in 2025 include Danaher (Cytiva), Thermo Fisher Scientific, Sartorius AG, Merck Millipore, Eppendorf AG, Solaris Biotech, Applikon Biotechnology, Praj Hipurity Systems, Austar, and Infors HT. These firms collectively supply the majority of single-use, stainless-steel, and lab-scale systems globally.
Q2. What is driving demand for bioreactors in 2025?
Demand is driven by biologics production (USD 12.5 billion), cell & gene therapies (200+ active clinical trials), vaccine manufacturing (5+ billion doses annually), and biosimilar expansion in Asia and Europe. Food-tech and cultivated meat sectors also increasingly rely on bioreactors.
Q3. Which type of bioreactor is most in demand?
Single-use bioreactors (SUBs) are the fastest growing, accounting for ~USD 8.6 billion or 38% of market value in 2025. Stainless-steel systems still hold ~USD 10.5 billion (~45%), while wave, airlift, and modular systems contribute the rest.
Q4. Which regions are expanding fastest?
Asia-Pacific shows the highest growth, valued at USD 4.5 billion with more than 220 new CMO facilities announced in China, India, South Korea, and Singapore. North America remains the largest market (~40% share), while Europe emphasizes sustainability in its bioprocessing infrastructure.
Q5. How are companies investing in 2025?
- Thermo Fisher: launched a 5,000L HyPerforma DynaDrive system and opened a Singapore facility.
- Sartorius: expanded sites in France and the U.S. to meet single-use demand.
- Danaher/Cytiva: built AI-driven monitoring tools and expanded capacity in Massachusetts & Switzerland.
- Merck Millipore: opened an R&D center in Massachusetts to strengthen upstream innovation.
Q6. What role do CMOs/contract manufacturers play?
CMOs account for ~1,700 projects globally in 2025 requiring upgraded upstream suites, making them critical customers for 500L–5,000L single-use bioreactors and hybrid stainless-steel systems.
Q7. What are the main challenges in 2025?
Key challenges include supply chain resilience for single-use consumables, workforce shortages (over 10,000 skilled technicians needed globally), and the push for sustainable manufacturing processes to reduce energy and water consumption.
Q8. Are bioreactors used outside of pharma?
Yes. Beyond pharma and biotech, bioreactors are vital in food technology (cultivated meat, fermentation proteins worth USD 3.4 billion in 2025), academic research (USD 4.5 billion segment), and industrial bio-based material production.
Q9. What are the future opportunities for bioreactor companies?
Future opportunities include: scaling cell & gene therapy production, expanding biosimilar manufacturing in Asia, driving sustainability innovations in Europe, and enabling new food-tech applications such as fermentation-derived proteins. Companies combining single-use flexibility, digital monitoring, and regional manufacturing capacity are positioned to lead the next phase of industry growth.
Conclusion — Bioreactor Market 2025
The global bioreactor industry in 2025 stands as a cornerstone of modern biotechnology, valued at nearly USD 22.8 billion with an installed base of more than 65,000 active systems worldwide. Its impact extends across pharmaceutical production, academic research, food technology, and industrial applications, making it one of the most strategically important sectors in life sciences and beyond.
Across regions, North America maintains leadership with USD 9.0 billion in market value, fueled by advanced therapy production and contract manufacturing expansions. Europe follows with USD 6.8 billion, emphasizing sustainability, biosimilars, and strong academic-industry collaboration. Asia-Pacific, valued at USD 4.5 billion, has become the fastest-expanding hub, driven by vaccine scale-up and biosimilar adoption, particularly in China and India. Meanwhile, the Middle East, Africa, and Latin America contribute a combined USD 2.5 billion, with opportunities centered around government-backed vaccine projects and modernization of academic and pilot facilities.
From a competitive landscape standpoint, companies such as Danaher (Cytiva), Thermo Fisher Scientific, Sartorius AG, and Merck Millipore dominate the global single-use and integrated systems segment, while Eppendorf, Applikon, Solaris, Infors HT, and Solida Biotech sustain leadership in benchtop and pilot-scale applications. Regional specialists like Praj Hipurity Systems in India, Austar in China, and Celltain Biotech enhance local supply chain resilience and provide competitive solutions tailored to emerging markets.
The industry’s evolution in 2025 highlights clear themes:
- Shift to single-use systems, which now account for ~38% of installations, offering speed, flexibility, and contamination control.
- Integration of digital and AI-driven monitoring, adopted by more than 2,500 facilities globally, transforming how upstream processes are optimized.
- Sustainability and efficiency, with Europe leading the move toward energy-efficient, eco-friendly designs.
- Expansion of CMOs and cell/gene therapy facilities, with over 1,700 global projects requiring bioreactor upgrades in 2025.
In conclusion, bioreactors are no longer just laboratory equipment — they are strategic assets driving the global shift toward biologics, biosimilars, vaccines, advanced therapies, and sustainable bioproduction. Companies that combine technological innovation, geographic reach, and agile supply chains are positioned to capture the next wave of opportunities, while regions that invest in bioprocess infrastructure will shape the competitive landscape of biotechnology for the next decade.